Sweden: Renewed loan agreement provides Oncopeptides access to €30m facility

Nasdaq Stockholm-listed Oncopeptides, a global biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, has entered into a renewed unsecured loan facility agreement with the European Investment Bank (EIB), granting access to a conditional facility of up to €30m (US$31m). The loan is divided into three tranches, each with a five-year…

You must be a HMI Subscriber to view this content.

Subscribe Now »